Skip to main content

Table 2 Univariate and multivariate cox hazards analysis of the training cohort

From: A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy

 

Univariate analysis

Multivariate analysis

Characteristic

HR (95% CI)

P

HR (95% CI)

p

Sex

 Male/Female

1.577 (1.163–2.138)

0.003

1.655 (1.191–2.300)

0.003

Tumor size(cm)

 <3/3–5/≥5

1.274 (1.093–1.484)

0.002

  

Tumor multiplicity

 Single/Multiple

1.514 (1.160–1.976)

0.002

  

Cirrhosis

 Yes/N0

2.265 (1.201–4.271)

0.012

  

PVTT

 Yes/N0

2.052 (1.497–2.811)

<0.001

1.547 (1.162–2.059)

0.003

Ascites

 Yes/N0

2.314 (1.779–3.010)

<0.001

1.304 (0.918–1.852)

0.138

HBsAg

 Positive/Negative

0.622 (0.459–0.844)

0.002

  

NLR

 <5, ≥5

1.723 (1.246–2.384)

0.001

  

HGB(g/L)

 <120, ≥120

0.447 (0.343–0.581)

<0.001

0.785 (0.568–1.084)

0.142

PLT(*10^9/L)

 <100,≥100

0.690 (0.503–0.948)

0.022

  

CR (μmoI/L)

 <111, ≥111

3.486 (2.116–5.745)

<0.001

2.200 (1.254–3.858)

0.006

AST(U/L)

 <40, ≥40

1.908 (1.463–2.489)

<0.001

  

TBIL (μmol/L)

 <18.8, ≥18.8

1.602 (1.232–2.084)

<0.001

  

ALB(g/L)

  < 40, ≥40

0.468 (0.342–0.639)

<0.001

  

LDH(U/L)

 <250, ≥250

1.993 (1.389–2.861)

<0.001

  

GGT (U/L)

 <60, ≥60

2.147 (1.647–2.799)

<0.001

1.495 (1.087–2.056)

0.013

PTA(%)

  < 70, ≥70

0.574 (0.440–0.748)

<0.001

  

CA199(u/ml)

 <37, ≥37

2.479 (1.738–3.534)

<0.001

  

CRP (mg/L)

 <5, ≥5

2.545 (1.955–3.313)

<0.001

1.823 (1.341–2.478)

<0.001